CASC
EVGN icon

Coppell Advisory Solutions Corp’s Evogene EVGN Stock Holding History

Coppell Advisory Solutions Corp’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-6
Closed -$42 – 475
2022
Q4 		$42 Buy
+6
New +$42 ﹤0.01% 1171

Other funds holding EVGN

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
JIC
Joel Isaacson & Co New York $3.02B AUM 21.81% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Coppell Advisory Solutions Corp's EVGN Position: Q1 2023 in Review

Coppell Advisory Solutions Corp sold out of Evogene (EVGN) in Q1 2023, closing a stake of 6 shares — an estimated $42 sold.

Coppell Advisory Solutions Corp first reported a position in EVGN in Q4 2022 and held it in 1 quarter. The position peaked at $42 in Q4 2022. 27 funds tracked by Wall St. Rank hold EVGN as of Q1 2023.

  • Coppell Advisory Solutions Corp reported no remaining Evogene position as of Q1 2023 after selling out during the quarter.
  • Coppell Advisory Solutions Corp sold 6 Evogene shares in Q1 2023, an estimated $42.
  • Coppell Advisory Solutions Corp first reported a position in Evogene in Q4 2022 and held it in 1 quarter.
  • Coppell Advisory Solutions Corp's Evogene position peaked at $42 in Q4 2022.
  • 27 funds tracked by Wall St. Rank held Evogene as of Q1 2023.

Based on Coppell Advisory Solutions Corp's 13F filing for Q1 2023, filed 10 May 2023.